CJC-1295 without DAC 5mg
CJC-1295 Without DAC 5mg – Research Peptide
Product OverviewThis product contains Modified GRF 1-29 (commonly referred to as CJC-1295 without DAC) at a concentration of 5mg per vial. It is a 29-amino-acid growth hormone–releasing factor analog designed for research applications. Unlike DAC-modified versions, this format does not include a Drug Affinity Complex, making it suitable for studying shorter-duration signaling activity. Supplied as a high-purity lyophilized powder.
Mechanism of ActionIn research environments, CJC-1295 without DAC activates GHRH receptors with a rapid onset and relatively short duration. It stimulates intracellular signaling pathways, including cAMP activity, in somatotroph cells. Due to its faster clearance, it is commonly used to examine acute and pulsatile growth hormone responses rather than prolonged signaling effects.
Research BackgroundEarly studies, including work by Raun et al., helped define the receptor activity and stability of GRF analogs with DPP-IV resistance. Additional research, such as Bowers et al. (2003), has highlighted the differences between short-acting and long-acting formulations, particularly in terms of growth hormone release patterns. These findings support its use in controlled studies focused on short-term GH dynamics.
Product Specifications & Storage
Form: White to off-white lyophilized powder
Quantity: 5mg per vial
Storage: Store at -20°C in a dry, light-protected environment
Reconstitution: Sterile saline or bacteriostatic water
Shelf life: Up to 24 months when properly stored
Purity: >99% (HPLC tested)
Molecular weight: ~3.4 kDa
Approximate half-life: 2–3 hours (preclinical models)
DisclaimerFor research use only. Not intended for human consumption, medical use, or therapeutic purposes. All information is based on preclinical research. Proper regulatory approval is required for laboratory use.
